RegulatoryCompany release

Processa wins FDA IND clearance for Phase 2 oral BTK inhibitor VT-7208 in urticaria

🇺🇸 Processa Pharmaceuticals, Inc. (PCSA) · Thu 29 Oct 2026

The US company also signed an option deal with Generian for an oral FcRn antagonist and appointed Sheila Gujrathi as Executive Chair after acquiring Vidya Therapeutics.

Processa Pharmaceuticals announced on 29 October 2026 that the US Food and Drug Administration has cleared its investigational new drug (IND) application for a Phase 2 study of VT-7208, an oral Bruton's tyrosine kinase (BTK) inhibitor. The study will involve adults with moderate-to-severe chronic spontaneous urticaria (CSU).

According to the company, the planned trial is placebo-controlled and would enrol about 120 patients over a 12-week period. No further design details were available in the information provided.

Processa also reported a research collaboration and exclusive option agreement with Generian covering an oral neonatal Fc receptor (FcRn) antagonist. The financial and development terms of the arrangement were not available in the material reviewed.

The company further named Sheila Gujrathi as Executive Chair. These developments follow Processa's acquisition of Vidya Therapeutics in June 2026.

For context, an IND clearance allows a sponsor to begin clinical testing of an investigational medicine in the US, and it is not an indication of efficacy or eventual approval.

What it means for your team

  • Regulatory teams tracking CSU should note that another oral BTK inhibitor is moving into Phase 2 in the US, with a placebo-controlled design.
  • Clinical and PV teams may wish to follow the trial for safety reporting plans once the study is registered and details are published.
  • The Generian option deal signals Processa's interest in oral FcRn approaches, but terms are undisclosed, so any pipeline implications remain unclear.

Company's press release (SEC filing): Processa Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Processa Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →